Evidence map›Paper›PMID 38636130›Full record

ArticleEuropean journal of medicinal chemistry2024

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.

Christopher R M Asquith, Michael P East, Tuomo Laitinen, Carla Alamillo-Ferrer, Erkka Hartikainen, Carrow I Wells, Alison D Axtman, David H Drewry, Graham J Tizzard, Antti Poso and 2 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Christopher R M AsquithDepartment of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, NC, 27599, USA; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211, Kuopio, Finland; Structural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: christopher.asquith@uef.fi.
Michael P EastDepartment of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, NC, 27599, USA.
Tuomo LaitinenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211, Kuopio, Finland.
Carla Alamillo-FerrerStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Erkka HartikainenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211, Kuopio, Finland.
Carrow I WellsStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Alison D AxtmanStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
David H DrewryStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Graham J TizzardUK National Crystallography Service, School of Chemistry, University of Southampton, Highfield Campus, Southampton, SO17 1BJ, UK.
Antti PosoSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211, Kuopio, Finland.
Timothy M WillsonStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Gary L JohnsonDepartment of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, NC, 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: gary_johnson@med.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Eastern Finland · FIUniversity of Southampton · GB

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
SToP Cancer SPORE: Developmental Research ProgramP50CA257911 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jen Jen Yeh · 2022 to 2026
$12.9M
Integrating tumor and stroma to understand and predict treatment responseU01CA274298 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Naim Ur Rashid, Susan Tsai · 2022 to 2026
$4.7M
Targeted EGFR for basal subtype pancreatic cancerR01CA288145 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARY L. JOHNSON, Jen Jen Yeh · 2024 to 2026
$1.9M
NCI NIH HHS P50 CA257911NCI NIH HHS R01 CA288145NCI NIH HHS U01 CA274298NIDDK NIH HHS U24 DK116204Wellcome Trust
6 · The paper itself

Abstract

The oxindole scaffold has been the center of several kinase drug discovery programs, some of which have led to approved medicines. A series of two oxindole matched pairs from the literature were identified where TLK2 was potently inhibited as an off-target kinase. The oxindole has long been considered a promiscuous kinase inhibitor template, but across these four specific literature oxindoles TLK2 activity was consistent, while the kinome profile was radically different ranging from narrow to broad spectrum kinome coverage. We synthesized a large series of analogues, utilizing quantitative structure-activity relationship (QSAR) analysis, water mapping of the kinase ATP binding sites, kinome profiling, and small-molecule x-ray structural analysis to optimize TLK2 inhibition and kinome selectivity. This resulted in the identification of several narrow spectrum, sub-family selective, chemical tool compounds including 128 (UNC-CA2-103) that could enable elucidation of TLK2 biology.

Indexed as

Drug DiscoveryProtein Kinase InhibitorsQuantitative Structure-Activity RelationshipDose-Response Relationship, DrugHumansModels, MolecularMolecular StructureOxindolesProtein Serine-Threonine KinasesOxindolesProtein Kinase InhibitorsProtein Serine-Threonine KinasesKinase chemical toolKinase inhibitorsOxindoleQuantitative structure-activity relationship (QSAR)Tousled like kinase 2 (TLK2)

Identifiers

PMID38636130
PMCPMC11421834
OpenAlexW4393952511

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.